Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity

Avent, M. L., Rogers, B. A., Cheng, A. C. and Paterson, D. L. (2011) Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Internal Medicine Journal, 41 6: 441-449. doi:10.1111/j.1445-5994.2011.02452.x

Author Avent, M. L.
Rogers, B. A.
Cheng, A. C.
Paterson, D. L.
Title Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity
Journal name Internal Medicine Journal   Check publisher's open access policy
ISSN 1444-0903
Publication date 2011-06-01
Year available 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/j.1445-5994.2011.02452.x
Open Access Status Not yet assessed
Volume 41
Issue 6
Start page 441
End page 449
Total pages 9
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Language eng
Subject 2724 Internal Medicine
Abstract The new Australian Therapeutic Guidelines: Antibiotic, version 14 have revised the recommendations for the use and monitoring of aminoglycosides. The guidelines have clear distinctions between empirical and directed therapy as well as revised recommendations about the monitoring of aminoglycosides. This has led many clinicians to review their current practice with regard to the use of aminoglycosides. This review summarizes why aminoglycosides are still a valid treatment option and discusses the rationale for current dosing regimens in Gram-negative infections. In particular it focuses on the various methods for monitoring aminoglycosides that are currently being used. The aminoglycoside monitoring methods can be categorized into three groups: linear regression analysis (one compartment model), population methods and Bayesian estimation procedures. Although the population methods are easy to use and require minimal resources they can recommend clinically inappropriate doses as they have constant pharmacokinetic parameters and are not valid in special population groups, that is, renal impairment. The linear regression and Bayesian methods recommend more accurate dosage regimens; however, they require additional resources, such as information technology and healthcare personnel with background training in pharmacokinetics. The Bayesian methods offer additional advantages, such as calculation of doses based on a single serum concentration and optimization of the patient's previous pharmacokinetic data, in order to determine subsequent dosage regimens. We recommend the Bayesian estimation procedures be used, wherever feasible. However, they require the expertise of healthcare practitioners with a good understanding of pharmacokinetic principles, such as clinical pharmacists/clinical pharmacologists, in order to make appropriate recommendations.
Keyword Medicine, General & Internal
General & Internal Medicine
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
Official 2012 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 63 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 81 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 12 Oct 2011, 21:11:22 EST by Matthew Lamb on behalf of School of Medicine